Ann E. Berman - 29 Jul 2021 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: Director
Issuer ticker: IMRX
Reported as of: 29 Jul 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jul 2021, 16:27:35 UTC
Prior SEC filing: 02 Jun 2021
Next SEC filing: 04 Aug 2021
Source filing: View source filing
Reporting owner signature: By: /s/ Michael D. Bookman, Attorney-in-Fact for Ann E. Berman

Key filing fact

Ann E. Berman filed Form 4 for Immuneering Corp (IMRX) on 30 Jul 2021.

Key facts

This page summarizes Ann E. Berman's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jul 2021, 16:27.

Change

Previous filing in this sequence was filed on 02 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMRX transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: -28,371
Change %: -50%
Price: $0.000000
Shares after: 28,371
Date: 29 Jul 2021
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 28,371
Exercise price: $15.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable as to 25% of the underlying shares on July 29, 2022 and then in equal monthly installments over the subsequent three years, subject to Ms. Berman's continued service as a non-employee member of the Issuer's board of directors through each applicable vesting date.